Johnson & Johnson (NYSE:JNJ) Shares Bought by Czech National Bank

Czech National Bank boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 552,976 shares of the company's stock after acquiring an additional 30,955 shares during the quarter. Johnson & Johnson comprises about 0.8% of Czech National Bank's investment portfolio, making the stock its 19th biggest position. Czech National Bank's holdings in Johnson & Johnson were worth $91,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson in the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth about $32,000. Conquis Financial LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at $33,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Johnson & Johnson in the fourth quarter worth $36,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.2%

JNJ stock traded down $0.38 on Wednesday, hitting $154.04. 2,859,301 shares of the company's stock were exchanged, compared to its average volume of 7,927,677. The firm has a 50 day moving average price of $154.01 and a two-hundred day moving average price of $153.68. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The stock has a market cap of $370.63 billion, a P/E ratio of 23.16, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.38%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Analyst Ratings Changes

A number of research analysts have recently commented on JNJ shares. Bank of America cut their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Morgan Stanley lifted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Finally, Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.